ARTICLE | Clinical News
AdreView regulatory update
September 22, 2008 7:00 AM UTC
FDA approved an NDA from General Electric's GE Healthcare unit for AdreView as a molecular imaging agent to detect neuroendocrine tumors. The company plans to launch the iobenguane I 123 injection, wh...